These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Epilepsy: taming the seizures, dispelling the myths. Hingley AT FDA Consum; 1999; 33(1):28-32. PubMed ID: 10030144 [No Abstract] [Full Text] [Related]
24. Criteria for use of felbamate in adult, adolescent, and child inpatients and outpatients. Luer MS Am J Hosp Pharm; 1994 Jul; 51(13):1701-3; Quiz 1704-5. PubMed ID: 7942896 [No Abstract] [Full Text] [Related]
26. Alternative analyses for antiepileptic drug trials. Pledger GW; Sahlroot JT Epilepsy Res Suppl; 1993; 10():167-74. PubMed ID: 8251092 [No Abstract] [Full Text] [Related]
27. [Autopsy case of aplastic anemia suspected to be caused by anticonvulsants]. Nakaya Y; Kitagawa S; Takase S; Kawai K; Sawabu N Naika; 1971; 28(5):946-9. PubMed ID: 5140296 [No Abstract] [Full Text] [Related]
34. [Hemopathies caused by drugs in children: aplastic anemia, agranulocytosis, megaloblastic anemia]. Masera G; Baronciani D; Conti A; Jankovic M; Uderzo C Minerva Pediatr; 1978 Sep; 30(18):1463-72. PubMed ID: 703709 [No Abstract] [Full Text] [Related]
35. Phenobarbital-associated bone marrow aplasia: a case report and review of the literature. Focosi D; Kast RE; Benedetti E; Papineschi F; Galimberti S; Petrini M Acta Haematol; 2008; 119(1):18-21. PubMed ID: 18230962 [TBL] [Abstract][Full Text] [Related]
36. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation. Struve CT Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895 [No Abstract] [Full Text] [Related]
37. Postmarketing modifications in the safety labeling of the new antiepileptics. Buck ML; Gurka MJ; Goodkin HP Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758 [No Abstract] [Full Text] [Related]
38. FDA proposes higher fees for drug approvals to cover postmarketing surveillance. Tanne JH BMJ; 2007 Jan; 334(7586):177. PubMed ID: 17255596 [No Abstract] [Full Text] [Related]
40. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance. Ball R; Robb M; Anderson SA; Dal Pan G Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]